On May 13, 2026 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, reported that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present and participate in one-on-one meetings with investors at upcoming investor conferences.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Stifel 2026 Virtual Targeted Oncology Forum
Date/ Time: Wednesday, May 20, 2026, at 10 AM ET
Webcast Link: Stifel / Candel Presentation
2026 Jefferies Global Healthcare Conference (New York, NY)
Date/Time: Wednesday, June 3, 2026, at 5:30 PM ET
Webcast Link: Jefferies / Candel Presentation
Live webcasts of the presentations will be available by selecting Events and Presentations under the News & Events tab in the Investors section on www.candeltx.com. A replay of the webcasts will be archived for up to 90 days following the session date.
(Press release, Candel Therapeutics, MAY 13, 2026, View Source [SID1234665646])